Effect of the PA‑MSHA vaccine on septic serum‑induced inflammatory response

Liu,Xiang‑Feng; Wang,Li; Qu,Yi; Zhong,De-Wu; Miao,Xiong-Ying; Yao,Hong‑Liang

doi:10.3892/mmr.2013.1337

Effect of the PA‑MSHA vaccine on septic serum‑induced inflammatory response

Authors:
- Xiang‑Feng Liu
- Li Wang
- Yi Qu
- De-Wu Zhong
- Xiong-Ying Miao
- Hong‑Liang Yao
View Affiliations

Affiliations: Department of General Surgery, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, P.R. China, Department of Cardiothoracic Surgery, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, P.R. China, Hunan Provincial People's Hospital, Changsha, Hunan 410011, P.R. China
Published online on: February 21, 2013 https://doi.org/10.3892/mmr.2013.1337
Pages: 1350-1354

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sepsis is defined as a complex clinical syndrome caused by a serious infection followed by an amplified and deregulated inflammatory response. The complex syndrome is associated with a high rate of morbidity and mortality, despite substantial clinical advances. A vaccine derived from the outer membrane proteins of the Gram‑negative bacteria Pseudomonas aeruginosa (PA‑MSHA) has been demonstrated to exhibit immune modulatory properties. In the present study, the effect of the PA‑MSHA vaccine on the inflammatory response induced by serum from septic patients in peripheral blood mononuclear cells was determined. It was observed that PA‑MSHA pretreatment inhibits the production of septic serum‑induced tumor necrosis factor‑α. In addition, PA‑MSHA treatment increases interleukin‑10 levels and promotes the generation of CD4+CD25+Foxp3+ T cells. Thus, the results of the current study provide mechanistic insight relevant to the potential application of PA‑MSHA in the treatment of sepsis.

View Figures

View References

1	Bone RC, Balk RA, Cerra FB, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee American College of Chest Physicians/Society of Critical Care Medicine. Chest. 101:1644–1655. 1992. View Article : Google Scholar
2	Warren HS: Strategies for the treatment of sepsis. N Engl J Med. 336:952–953. 1997. View Article : Google Scholar : PubMed/NCBI
3	Stone R: Search for sepsis drugs goes on despite past failures. Science. 264:365–367. 1994. View Article : Google Scholar : PubMed/NCBI
4	Hotchkiss RS and Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med. 348:138–150. 2003. View Article : Google Scholar : PubMed/NCBI
5	Curns AT, Steiner CA, Sejvar JJ and Schonberger LB: Hospital charges attributable to a primary diagnosis of infectious diseases in older adults in the United States, 1998 to 2004. J Am Geriatr Soc. 56:969–975. 2008. View Article : Google Scholar : PubMed/NCBI
6	Fukazawa A, Yokoi Y, Kurachi K, et al: Implication of B lymphocytes in endotoxin-induced hepatic injury after partial hepatectomy in rats. J Surg Res. 137:21–29. 2007. View Article : Google Scholar : PubMed/NCBI
7	Garcea G and Maddern GJ: Liver failure after major hepatic resection. J Hepatobiliary Pancreat Surg. 16:145–155. 2009. View Article : Google Scholar : PubMed/NCBI
8	Wright AJ, Unger S, Coleman BL, Lam PP and McGeer AJ: Maternal antibiotic exposure and risk of antibiotic resistance in neonatal early-onset sepsis: a case-cohort study. Pediatr Infect Dis J. 31:1206–1208. 2012. View Article : Google Scholar : PubMed/NCBI
9	Lewis DH, Chan DL, Pinheiro D, Armitage-Chan E and Garden OA: The immunopathology of sepsis: pathogen recognition, systemic inflammation, the compensatory anti-inflammatory response and regulatory T cells. J Vet Intern Med. 26:457–482. 2012. View Article : Google Scholar : PubMed/NCBI
10	Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P and Yamaguchi T: Regulatory T cells: how do they suppress immune responses? Int Immunol. 21:1105–1111. 2009. View Article : Google Scholar : PubMed/NCBI
11	Workman CJ, Szymczak-Workman AL, Collison LW, Pillai MR and Vignali DA: The development and function of regulatory T cells. Cell Mol Life Sci. 66:2603–2622. 2009. View Article : Google Scholar : PubMed/NCBI
12	Shalev I, Schmelzle M, Robson SC and Levy G: Making sense of regulatory T cell suppressive function. Semin Immunol. 23:282–292. 2011. View Article : Google Scholar : PubMed/NCBI
13	Leng FY, Liu JL, Liu ZJ, Yin JY and Qu HP: Increased proportion of CD4(+)CD25(+)Foxp3(+) regulatory T cells during the early-stage sepsis in ICU patients. J Microbiol Immunol Infect. Aug 23–2012.(Epub ahead of print).
14	Monneret G, Debard AL, Venet F, et al: Marked elevation of human circulating CD4⁺CD25⁺ regulatory T cells in sepsis-induced immunoparalysis. Crit Care Med. 31:2068–2071. 2003. View Article : Google Scholar : PubMed/NCBI
15	Saito K, Wagatsuma T, Toyama H, et al: Sepsis is characterized by the increases in percentages of circulating CD4⁺CD25⁺ regulatory T cells and plasma levels of soluble CD25. Tohoku J Exp Med. 216:61–68. 2008. View Article : Google Scholar : PubMed/NCBI
16	Heuer JG, Zhang T, Zhao J, et al: Adoptive transfer of in vitro-stimulated CD4⁺CD25⁺ regulatory T cells increases bacterial clearance and improves survival in polymicrobial sepsis. J Immunol. 174:7141–7146. 2005.PubMed/NCBI
17	Scumpia PO, Delano MJ, Kelly KM, et al: Increased natural CD4⁺CD25⁺ regulatory T cells and their suppressor activity do not contribute to mortality in murine polymicrobial sepsis. J Immunol. 177:7943–7949. 2006.PubMed/NCBI
18	Wisnoski N, Chung CS, Chen Y, Huang X and Ayala A: The contribution of CD4⁺CD25⁺ T-regulatory-cells to immune suppression in sepsis. Shock. 27:251–257. 2007.PubMed/NCBI
19	Porwoll JM, Gebel HM, Rodey GE and Markham RB: In vitro response of human T cells to Pseudomonas aeruginosa. Infect Immun. 40:670–674. 1983.PubMed/NCBI
20	Lee N, Ahn B, Jung SB, Kim YG, Kim H and Park WJ: Conformation-dependent antibody response to Pseudomonas aeruginosa outer membrane proteins induced by immunization in humans. FEMS Immunol Med Microbiol. 27:79–85. 2000.
21	Mu XY: Success in establishing the MSHA-positive Pseudomonas aeruginosa fimbrial strain. Wei Sheng Wu Xue Bao. 26:176–179. 1986.(In Chinese).
22	Jia L, Wang C, Kong H, et al: Effect of PA-MSHA vaccine on plasma phospholipids metabolic profiling and the ratio of Th2/Th1 cells within immune organ of mouse IgA nephropathy. J Pharm Biomed Anal. 43:646–654. 2007. View Article : Google Scholar : PubMed/NCBI
23	Wu Y, Borde M, Heissmeyer V, et al: FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell. 126:375–387. 2006. View Article : Google Scholar : PubMed/NCBI
24	Mallat Z, Besnard S, Duriez M, et al: Protective role of interleukin-10 in atherosclerosis. Circ Res. 85:e17–e24. 1999. View Article : Google Scholar : PubMed/NCBI
25	Pinderski Oslund LJ, Hedrick CC, Olvera T, et al: Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol. 19:2847–2853. 1999.PubMed/NCBI
26	Ait-Oufella H, Taleb S, Mallat Z and Tedgui A: Cytokine network and T cell immunity in atherosclerosis. Semin Immunopathol. 31:23–33. 2009. View Article : Google Scholar : PubMed/NCBI
27	Davidson NJ, Leach MW, Fort MM, et al: T helper cell 1-type CD4⁺ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J Exp Med. 184:241–251. 1996.PubMed/NCBI
28	Damas P, Reuter A, Gysen P, Demonty J, Lamy M and Franchimont P: Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med. 17:975–978. 1989. View Article : Google Scholar : PubMed/NCBI
29	Girardin E, Grau GE, Dayer JM, Roux-Lombard P and Lambert PH: Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med. 319:397–400. 1988. View Article : Google Scholar : PubMed/NCBI